About the author

skinoncology.net is written by practising UK clinicians, led by a named Editor-in-Chief, and independently reviewed within specialty by its editorial board. The site is independent, self-funded, and not produced by any institution, learned society or commercial organisation.

Editor-in-Chief

Mr Masha Singh, FRCS(Plast) — Consultant Plastic, Reconstructive and Aesthetic Surgeon specialising in cutaneous malignancy. He founded and edits skinoncology.net and leads its surgical and reconstructive content. Full profile →

Specialty: Plastic & Reconstructive Surgery, sub-specialising in skin oncology and reconstruction.
Experience: Nearly 20 years' NHS practice across diagnosis, surgical treatment and reconstruction of cutaneous malignancy — melanoma, BCC, cSCC, Merkel cell carcinoma, cutaneous sarcomas and rare adnexal tumours.
Practice setting: UK NHS multidisciplinary skin cancer team. Active surgical caseload spanning lesion-directed treatment, complex local and free-flap reconstruction, and post-treatment surveillance.
Registration: GMC 6141386 — registered with a licence to practise; on the GMC Specialist Register for Plastic Surgery.

Conflicts of interest

No commercial sponsorship, advisory board honoraria or industry support relating to skinoncology.net. See the funding page for the standing declaration.

How the site is written and reviewed

Articles are authored by practising UK clinicians, led by the Editor-in-Chief, and reviewed within their specialty by the editorial board — plastic surgery, dermatology, pathology and radiology, with further specialties being added. Independent specialty review is being applied progressively across the site, beginning with the highest-stakes content.

Subject areas closest to the authors' daily practice (skin cancer surgery, margins, reconstruction, multidisciplinary workflow) are the most developed.
Areas that depend on another specialty — dermatopathology, imaging, medical oncology — are written closely against current UK national guidance and reviewed by the relevant board member as that review is completed.
Where evidence is contested, evolving or low quality, that is stated explicitly in the article.
Reader feedback and corrections are welcomed via the contact page and remain an important way the site improves.